CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

  • Shawn F. Johnson
  • , Cristina Cruz
  • , Ann Katrin Greifenberg
  • , Sofia Dust
  • , Daniel G. Stover
  • , David Chi
  • , Benjamin Primack
  • , Shiliang Cao
  • , Andrea J. Bernhardy
  • , Rhiannon Coulson
  • , Jean Bernard Lazaro
  • , Bose Kochupurakkal
  • , Heather Sun
  • , Christine Unitt
  • , Lisa A. Moreau
  • , Kristopher A. Sarosiek
  • , Maurizio Scaltriti
  • , Dejan Juric
  • , José Baselga
  • , Andrea Richardson
    • Scott Rodig, Alan D. D'Andrea, Judith Nã Balma, Neil Johnson, Matthias Geyer, Violeta Serra, Elgene Lim, Geoffrey I. Shapiro

Research output: Contribution to journal › Article › peer-review

236 Scopus citations

Fingerprint

Dive into the research topics of 'CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science